ADC Target Selection Summit on December 10-12, 2024 in San Diego, United States

Welcome to the 4th ADC Target Selection Summit! Get the First Most Important Decision Right.

The ADC field continues to grow, saturating the industry and demanding continuous innovation to leave your work in the field. For this reason, biopharma and biotech are shifting attention to advanced target selection methods to source novel routes for ADC therapeutic activity.

The 4th ADC Target Selection Summit has been created for those professionals seeking to develop a first-in-class ADC through innovation in the target.

From honing into the complex mechanistic biology around the target to implementing advanced computational approaches to screen potential targets, don't miss this opportunity to place novel targeting as a high priority.

URLs:

Tickets: https://go.evvnt.com/2637829-2?pid=10008

Brochure: https://go.evvnt.com/2637829-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4297.00,

Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,

Academic Pricing - 3 Day Pass (Conference + Workshop Day): USD 3697.00,

Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,

Solution Providers Pricing - 3 Day Pass (Conference + Workshop Day): USD 5297.00,

Solution Providers Pricing - 2 Day Pass (Conference Only): USD 3799.00

Speakers: Andrew Zhang, Director, Chemical Biology, Former Astrazeneca, Bill Mallet, Senior Director, Target Validation, Bolt Biotherapeutics, Daniel Celarese, Senior Director, Innovation and Strategy, Sutro Biopharma, Dowdy Jackson, Chief Executive Officer, Jackson Consulting Group, Hans Wandall, Chief Scientific Officer, GO Therapeutics, Jan Pinkas, Chief Scientific Officer, Pyxis Oncology, Mark Wappett, Head of Bioinformatics and Data Science, Almac Discovery, Massimo Masiero, Associate Director, Molecular Pharmacology, Bicycle Therapeutics, Matthew Metzger, Program, Alliance and Business Development Manager, Oxford Biotherapeutics, Neil Cashman, Chief Scientific Officer, Epifold, Paul Song, Chief Scientific Officer, GeneQuantum Biosciences, Rakesh Dixit, President and Chief Executive Officer, Bionavigen, Robert Lawrence, Director of Biology, Immunome, Sayumi Yamazoe, Associate Director, ADC Discovery Protein Engineer, Bristol Myers Squibb, Xi Zhao, Computational Oncology, Research and Early Development Professional, Abbvie, Zhu Chen, Senior Vice President, Genmab